Banting Memorial Lecture 2016 Reducing lifetime risk of complications in adolescents with Type 1 diabetes

Diabetic Medicine

Volumn 34, Issue 4, 2017, Pages 460-466

  Dunger, D B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ANTIDIABETIC AGENT;

ADOLESCENT; ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LONGITUDINAL STUDY; MICROALBUMINURIA; PUBERTY; PUMP; REVIEW; SCREENING TEST; URINARY EXCRETION; COMPLICATION; DIABETIC COMPLICATION; GLUCOSE BLOOD LEVEL; INSULIN INFUSION; METABOLISM; RISK REDUCTION;

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; RISK REDUCTION BEHAVIOR;

EID: 85010338151     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13299     Document Type: Review

References (50)

1. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996; 313: 779–784.
2. Morgan E, Cardwell CR, Black CJ, McCance DR, Patterson CC. Excess mortality in Type 1 diabetes diagnosed in childhood and adolescence: a systematic review of population-based cohorts. Acta Diabetol 2015; 52: 801–807.
3. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 2015; 313: 37–44.
4. Petrie D, Lung TWC, Rawshani A, Palmer AJ, Svensson A-M, Eliasson B et al. Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia 2016; 59: 1167–1176.
5. Huo L, Harding JL, Peeters A, Shaw JE, Magliano DJ. Life expectancy of type 1 diabetic patients during 1997–2010: a national Australian registry-based cohort study. Diabetologia 2016; 59: 1177–1185.
6. Brown LJ, Scott RS, Moir CL. All-cause mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population. Diabetes Care 2001; 24: 56–63.
7. Katz M, Laffel L. Mortality in type 1 diabetes in the current era: two steps forward, one step backward. JAMA 2015; 313: 35–36.
8. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430–1432.
9. Mathiesen ER, Saurbrey N, Hommel E, Parving HH. Prevalence of microalbuminuria in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1986; 29: 640–643.
10. Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35: 1049–1054.
11. Dahlquist G, Rudberg S. The prevalence of microalbuminuria in diabetic children and adolescents and its relation to puberty. Acta Paediatr Scand 1987; 76: 795–800.
12. Gardner SG, Bingley PJ, Sawtell PA, Weeks S, Gale EA. Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis. The Bart's–Oxford Study Group. BMJ 1997; 315: 713–717.
13. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999; 22: 495–502.
14. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008; 336: 697–701.
15. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004; 328: 1105.
16. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008; 337: a918.
17. Benitez-Aguirre P, Craig ME, Cass HG, Sugden CJ, Jenkins AJ, Wang JJ et al. Sex differences in retinal microvasculature through puberty in type 1 diabetes: are girls at greater risk of diabetic microvascular complications? Invest Ophthalmol Vis Sci 2015; 56: 571–577.
18. Cho YH, Craig ME, Donaghue KC. Puberty as an accelerator for diabetes complications. Pediatr Diabetes 2014; 15: 18–26.
19. Hietala K, Harjutsalo V, Forsblom C, Summanen P, Groop P-H. FinnDiane Study Group. Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care 2010; 33: 1315–1319.
20. Marcovecchio ML, Tossavainen PH, Dunger DB. Prevention and treatment of microvascular disease in childhood type 1 diabetes. Br Med Bull 2010; 94: 145–164.
21. Donaghue KC, Wadwa RP, Dimeglio LA, Wong TY, Chiarelli F, Marcovecchio ML et al. Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes 2014; 15(Suppl 20): 257–269.
22. Maahs DM, Daniels SR, de Ferranti SD, Dichek HL, Flynn J, Goldstein BI et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation 2014; 130: 1532–1558.
23. Amin R, Williams RM, Frystyk J, Umpleby M, Matthews D, Orskov H et al. Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study. Clin Endocrinol (Oxf) 2005; 62: 137–144.
24. Amin R, Schultz C, Ong K, Frystyk J, Dalton RN, Perry L et al. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care 2003; 26: 1456–1461.
25. Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, Cooper JD et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 2009; 32: 658–663.
26. Marcovecchio ML, Dalton RN, Schwarze CP, Prevost AT, Neil HAW, Acerini CL et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 2009; 52: 1173–1181.
27. Marcovecchio ML, Dalton RN, Turner C, Prevost AT, Widmer B, Amin R et al. Symmetric dimethylarginine, an endogenous marker of glomerular filtration rate, and the risk for microalbuminuria in young people with type 1 diabetes. Arch Dis Child 2010; 95: 119–124.
28. Marcovecchio ML, Giannini C, Dalton RN, Widmer B, Chiarelli F, Dunger DB. Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with Type 1 diabetes developing microalbuminuria. Diabet Med 2009; 26: 815–819.
29. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3: 514–525.
30. Marcovecchio ML, Tossavainen PH, Acerini CL, Barrett TG, Edge J, Neil A et al. Maternal but not paternal association of ambulatory blood pressure with albumin excretion in young offspring with type 1 diabetes. Diabetes Care 2010; 33: 366–371.
31. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177–188.
32. Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014; 37: 39–43.
33. Pirola L. The DCCT/EDIC study: epigenetic clues after three decades. Diabetes 2014; 63: 1460–1462.
34. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE et al. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci USA 2016; 113: E3002–3011.
35. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010; 59: 1244–1253.
36. Rewers MJ, Pillay K, de Beaufort C, Craig ME, Hanas R, Acerini CL et al. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014; 2014: 102–14.
37. American Diabetes Association. 11. Children and Adolescents. Diabetes Care. 2016; 39(Suppl 1): S86–S93.
38. National Institute for Health and Care Excellence (NICE). Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline [NG 18], August 2015. Available at https://www.nice.org.uk/guidance/ng18 Last accessed 8 December 2016.
39. Thabit H, Elleri D, Leelarathna L, Allen J, Lubina-Solomon A, Stadler M et al. Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. Lancet 2015; 385: S96.
40. Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015; 373: 2129–2140.
41. Maahs DM, Hermann JM, DuBose SN, Miller KM, Heidtmann B, DiMeglio LA et al. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia 2014; 57: 1578–1585.
42. Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38: 971–978.
43. National Paediatric Diabetes Audit 2013–2014. London: Royal College of Paediatrics and Child Health.
44. The Adolescent Type 1 Diabetes Cardio-renal Intervention Trial Research Group. Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT). BMC Pediatr 2009; 9: 79.
45. Dunger DB, Schwarze CP, Cooper JD, Widmer B, Neil HAW, Shield J et al. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria? Diabet Med 2007; 24: 131–136.
46. Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T et al. Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care 2014; 37: 805–813.
47. Maftei O, Pena AS, Sullivan T, Jones TW, Donaghue KC, Cameron FJ et al. Early atherosclerosis relates to urinary albumin excretion and cardiovascular risk factors in adolescents with type 1 diabetes: Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT). Diabetes Care 2014; 37: 3069–3075.
48. Cho YH, Craig ME, Davis EA, Cotterill AM, Couper JJ, Cameron FJ et al. Cardiac autonomic dysfunction is associated with high-risk albumin-to-creatinine ratio in young adolescents with type 1 diabetes in AdDIT (Adolescent type 1 Diabetes cardio-renal Interventional Trial). Diabetes Care 2015; 38: 676–681.
49. DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2: 793–800.
50. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298–2307.